The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older against fleas and ticks.

A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...

The transaction will enhance Merck's cardio-pulmonary pipeline and portfolio with the addition of Ohtuvayre, an FDA-approved COPD treatment.

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for the 2028 loss of ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Merck & Co has made another move towards diversifying its pipeline and reducing its reliance on blockbuster cancer drug Keytruda, pledging $525 million to an alliance with Synthekine initially ...

U.S. pharmaceutical firm Merck will purchase U.K.-based Verona Pharma for around $10 billion, the companies said Wednesday.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma’s new ch… ...